Regulatory Hurdles Cloud Hims & Hers' Growth Trajectory

Hims & Hers Q4 earnings beat estimates, but shares fall on weak revenue guidance due to FDA and legal challenges impacting its weight management segment.

The telehealth provider Hims & Hers Health, Inc. delivered a quarterly report marked by contrasting signals this week. While the company's bottom line outperformed expectations, a subdued revenue forecast for the current period has unsettled investors, sending its shares lower. The primary culprit is a series of regulatory challenges impacting its weight management segment.

Strong Earnings Overshadowed by Guidance Cut

For the fourth quarter of 2025, Hims & Hers posted earnings per share of $0.08, surpassing analyst consensus estimates of approximately $0.05. Quarterly revenue climbed 28% year-over-year to reach $617.8 million, though this figure came in just shy of the $619 million market forecast.

The full-year 2025 results showed significant growth, with revenue hitting $2.35 billion, a 59% increase from the prior year. Net income was reported at $128 million. The company's subscriber base expanded by 13%, exceeding 2.5 million members.

Investor focus, however, shifted to the company's outlook. Management issued first-quarter 2026 revenue guidance in a range of $600 million to $625 million, falling substantially below the anticipated $653 million. This revision is directly attributed to an expected $65 million revenue shortfall related to changes in the distribution of personalized weight loss medications.

FDA Scrutiny and Legal Challenges Mount

The disappointing forecast stems from intensified regulatory pressure on products containing semaglutid. The U.S. Food and Drug Administration (FDA) has moved to restrict the compounding of versions of the popular weight-loss injections Wegovy and Ozempic, manufactured by Novo Nordisk. This action followed the agency's declaration that the official drug shortage for these medications has ended.

In early February, Hims & Hers attempted to launch a semaglutide-based oral medication priced at $49 per month. The FDA intervened, referring the matter to the Department of Justice. Concurrently, Novo Nordisk filed a patent infringement lawsuit against the company. Adding to its legal complexities, Hims & Hers is also subject to an ongoing investigation by the Securities and Exchange Commission (SEC) concerning its disclosures related to GLP-1 therapies.

Long-Term Targets Remain Unchanged

Despite these near-term headwinds, the company's leadership reaffirmed its medium-term financial objectives. For the full 2026 fiscal year, Hims & Hers continues to project revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA expected to land between $300 million and $375 million. The midpoint of the revenue range aligns closely with the current analyst consensus estimate of $2.74 billion.

Company executives emphasized that the majority of its revenue is generated outside the weight management category. Its international business saw explosive growth in 2025, surging nearly 400% to $134 million. Furthermore, the acquisition of Australian digital health firm Eucalyptus for up to $1.15 billion is progressing and anticipated to close around mid-2026.

Market Analysts Adopt a Cautious Stance

In response to the report, investment bank BTIG downgraded its rating on the stock from "Buy" to "Neutral," citing the disappointing Q1 guidance, decelerating growth, and heightened legal overhangs. Analysts at Truist Securities noted that achieving the full-year targets now requires a significant acceleration in business performance throughout the remainder of the year.

While expansion into international markets and a diversified product portfolio provide a solid foundation for long-term growth, the immediate sentiment is being weighed down by the confluence of FDA actions, patent litigation, and regulatory scrutiny. The path forward, though guided by an unchanged annual outlook, appears fraught with increased near-term uncertainty.